The patent claim is stated as a “method of increasing GLP-1 levels in a subject in need thereof, comprising administering a composition comprising eriocitrin to the subject.”
Ingredients by Nature (IBN; Montclair, CA) announced the approval by the U.S. Patent and Trademark Office (USPTO) of a second patent for its use of eriocitrin. The patent claim is stated as a “method of increasing GLP-1 levels in a subject in need thereof, comprising administering a composition comprising eriocitrin to the subject.”
GLP-1 helps maintain appropriate levels of insulin secretion and glucose uptake, solidifying the ingredient’s usage by people with poor blood sugar, such as prediabetics. According to Ingredients by Nature, administering 50-600 mg of the citrus flavonoid may help increase GLP-1 levels. IBN’s previous patent was recently amended to increase the dosage of eriocitrin from 100-200 mg to 25-800 mg for the lowering of blood sugar.
“There are multiple facets to prediabetes management and increasing GLP-1 plays a vital role in helping to support healthy blood glucose levels,” said Rob Brewster, president of IBN, in a press release. “The approval of our second eriocitrin patent provides strong support for our efforts to raise awareness of the flavonoid’s multi-faceted potential. We also have several more very promising human clinicals in process and hope to see some of them published soon.”
Eriocitrin is the primary citrus flavonoid used in IBN’s Eriomin ingredient, which is available in two version: Eriomin Glucose for the management of prediabetes, and Eriomin Esport for a healthy gaming lifestyle, which also helps maintain healthy blood glucose levels.